AR033830A1 - Uso de los antagonistas de los receptores de la il-8 en el tratamiento de las infecciones viricas - Google Patents
Uso de los antagonistas de los receptores de la il-8 en el tratamiento de las infecciones viricasInfo
- Publication number
- AR033830A1 AR033830A1 ARP010103395A ARP010103395A AR033830A1 AR 033830 A1 AR033830 A1 AR 033830A1 AR P010103395 A ARP010103395 A AR P010103395A AR P010103395 A ARP010103395 A AR P010103395A AR 033830 A1 AR033830 A1 AR 033830A1
- Authority
- AR
- Argentina
- Prior art keywords
- antagonist
- manufacture
- viric
- antagonists
- infections
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 4
- 208000015181 infectious disease Diseases 0.000 title abstract 2
- 102000010681 interleukin-8 receptors Human genes 0.000 title abstract 2
- 108010038415 interleukin-8 receptors Proteins 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 206010006458 Bronchitis chronic Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 241000711573 Coronaviridae Species 0.000 abstract 1
- 241000709661 Enterovirus Species 0.000 abstract 1
- 241000430519 Human rhinovirus sp. Species 0.000 abstract 1
- 206010033078 Otitis media Diseases 0.000 abstract 1
- 206010035664 Pneumonia Diseases 0.000 abstract 1
- 241000725643 Respiratory syncytial virus Species 0.000 abstract 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 abstract 1
- 230000001387 anti-histamine Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 239000000739 antihistaminic agent Substances 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 208000007451 chronic bronchitis Diseases 0.000 abstract 1
- 201000009240 nasopharyngitis Diseases 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 241000701161 unidentified adenovirus Species 0.000 abstract 1
- 241001529453 unidentified herpesvirus Species 0.000 abstract 1
- 241000712461 unidentified influenza virus Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Uso de una cantidad efectiva de un antagonista de los receptores de la IL-8 para la manufactura de un medicamento para tratar la sintomatología del resfriado común causado por infección de rinovirus humano, otros enterovirus, herpesvirus, coronavirus, influenzavirus, parainfluenzavirus, virus respiratorio sincitial o adenovirus en un humano que lo necesite. Uso del antagonista mencionado en conjunción con un antihistamínico, un anti inflamatorio. Uso del antagonista en done se administra oralmente o por inhalación. Uso del antagonista para la manufactura de un medicamento para tratar el asma, bronquitis crónica, enfermedad pulmonar obstructiva crónica, otitis media, sinucitis y neumonía.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21905300P | 2000-07-18 | 2000-07-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR033830A1 true AR033830A1 (es) | 2004-01-07 |
Family
ID=22817645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010103395A AR033830A1 (es) | 2000-07-18 | 2001-07-16 | Uso de los antagonistas de los receptores de la il-8 en el tratamiento de las infecciones viricas |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1307190A4 (es) |
| JP (1) | JP2004509852A (es) |
| KR (1) | KR20030019587A (es) |
| CN (1) | CN1449285A (es) |
| AR (1) | AR033830A1 (es) |
| AU (1) | AU2001273497A1 (es) |
| BR (1) | BR0112603A (es) |
| CA (1) | CA2418162A1 (es) |
| CZ (1) | CZ2003132A3 (es) |
| HU (1) | HUP0300754A3 (es) |
| IL (1) | IL153921A0 (es) |
| MX (1) | MXPA03000500A (es) |
| NO (1) | NO20030201L (es) |
| NZ (1) | NZ523659A (es) |
| PL (1) | PL365886A1 (es) |
| WO (1) | WO2002005814A1 (es) |
| ZA (1) | ZA200300474B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060030550A1 (en) * | 2004-08-04 | 2006-02-09 | Lithgow Theodore L | Pharmaceutical formulations |
| PE20170185A1 (es) * | 2014-05-12 | 2017-04-01 | Glaxosmithkline Intellectual Property (No 2) Ltd | Composiciones farmaceuticas para tratar enfermedades infecciosas |
| BR112022018294A2 (pt) * | 2020-03-26 | 2023-01-10 | Dompe Farm Spa | Inibidores de cxcl8 para uso no tratamento de covid-19 |
| EP4008325A1 (en) * | 2020-12-02 | 2022-06-08 | Dompe' Farmaceutici S.P.A. | Cxcl8 inhibitors for use in the treatment of covid-19 |
| EP3884932A1 (en) * | 2020-03-26 | 2021-09-29 | Dompe' Farmaceutici S.P.A. | Cxcl8 inhibitors for use in the treatment of covid-19 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5547979A (en) * | 1992-03-30 | 1996-08-20 | Smithkline Beecham | TNF inhibition |
| WO1996005836A2 (en) * | 1994-08-25 | 1996-02-29 | Medical University Of South Carolina | Methods of treating cold symptoms using pentoxifylline |
| JPH11503110A (ja) * | 1995-02-17 | 1999-03-23 | スミスクライン・ビーチャム・コーポレイション | Ｉｌ−８受容体拮抗剤 |
| SE9802729D0 (sv) * | 1998-08-13 | 1998-08-13 | Astra Pharma Prod | Novel Compounds |
| SE9802937D0 (sv) * | 1998-09-01 | 1998-09-01 | Astra Pharma Prod | Novel compounds |
-
2001
- 2001-07-16 NZ NZ523659A patent/NZ523659A/en unknown
- 2001-07-16 EP EP01952777A patent/EP1307190A4/en not_active Withdrawn
- 2001-07-16 AR ARP010103395A patent/AR033830A1/es not_active Application Discontinuation
- 2001-07-16 CZ CZ2003132A patent/CZ2003132A3/cs unknown
- 2001-07-16 CN CN01813095A patent/CN1449285A/zh active Pending
- 2001-07-16 PL PL01365886A patent/PL365886A1/xx not_active Application Discontinuation
- 2001-07-16 CA CA002418162A patent/CA2418162A1/en not_active Abandoned
- 2001-07-16 KR KR10-2003-7000717A patent/KR20030019587A/ko not_active Withdrawn
- 2001-07-16 HU HU0300754A patent/HUP0300754A3/hu unknown
- 2001-07-16 AU AU2001273497A patent/AU2001273497A1/en not_active Abandoned
- 2001-07-16 WO PCT/US2001/022328 patent/WO2002005814A1/en not_active Ceased
- 2001-07-16 BR BR0112603-2A patent/BR0112603A/pt not_active IP Right Cessation
- 2001-07-16 JP JP2002511746A patent/JP2004509852A/ja not_active Withdrawn
- 2001-07-16 MX MXPA03000500A patent/MXPA03000500A/es unknown
- 2001-07-16 IL IL15392101A patent/IL153921A0/xx unknown
-
2003
- 2003-01-15 NO NO20030201A patent/NO20030201L/no not_active Application Discontinuation
- 2003-01-17 ZA ZA200300474A patent/ZA200300474B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1449285A (zh) | 2003-10-15 |
| NO20030201L (no) | 2003-03-17 |
| CA2418162A1 (en) | 2002-01-24 |
| NO20030201D0 (no) | 2003-01-15 |
| HUP0300754A3 (en) | 2009-03-02 |
| JP2004509852A (ja) | 2004-04-02 |
| EP1307190A1 (en) | 2003-05-07 |
| MXPA03000500A (es) | 2003-06-24 |
| ZA200300474B (en) | 2004-08-17 |
| BR0112603A (pt) | 2004-08-24 |
| AU2001273497A1 (en) | 2002-01-30 |
| IL153921A0 (en) | 2003-07-31 |
| EP1307190A4 (en) | 2007-08-22 |
| KR20030019587A (ko) | 2003-03-06 |
| CZ2003132A3 (cs) | 2003-09-17 |
| NZ523659A (en) | 2006-01-27 |
| WO2002005814A1 (en) | 2002-01-24 |
| PL365886A1 (en) | 2005-01-10 |
| HUP0300754A2 (hu) | 2003-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20073337L (no) | Fremgangsmater for behandling av andedrettssykdommer ved anvendelse av antagonister av interleukin-1 reseptor type 1 | |
| CY1108978T1 (el) | Συνδυασμος ενωσεων μεθυλξανθινης και στεροειδων για να θεραπευονται χρονιες αναπνευστικες ασθενειες | |
| ES2178943A1 (es) | Uso de compuestos organicos en el tratamiento de enfermedad pulmonar obstructiva cronica. | |
| CR8918A (es) | Derivados de triazolopiridinilsulfanilo como inhibidores de quinasa map p38 | |
| JP2023528810A (ja) | レムデシビル治療方法 | |
| MX2009003372A (es) | Formas de dosificacion de pelicula no mucoadhesiva. | |
| DK1326595T3 (da) | Administration af resveratrol til at behandle inflammatoriske respiratoriske lidelser | |
| ECSP088902A (es) | Derivados de pirazolo[3,4-d]-pirimidina utiles para tratar trastornos respiratorios | |
| CN115836079B (zh) | 烟酰胺单核苷酸和烟酰胺核苷衍生物及其在治疗特别是由流感病毒或冠状病毒引起的病毒感染和呼吸道并发症中的用途 | |
| NO20075287L (no) | Kombinasjon av antikolinergika og leukotnen-reseptorantagonister for behandling av andedrettslidelser | |
| KR20020032591A (ko) | 라이노바이러스 감염에서의 ｃｓａｉｄ의 용도 | |
| Du et al. | Lianhuaqingwen capsule inhibits influenza-induced bacterial adhesion to respiratory epithelial cells through down-regulation of cell adhesion molecules | |
| Awasthi et al. | OUTBREAK of novel corona virus disease (COVID-19): Antecedence and aftermath | |
| Turner | The common cold | |
| AR033830A1 (es) | Uso de los antagonistas de los receptores de la il-8 en el tratamiento de las infecciones viricas | |
| Majdalawieh et al. | Immunomodulatory and anti-inflammatory effects of berberine in lung tissue and its potential application in prophylaxis and treatment of COVID-19 | |
| Bonville et al. | Ribavirin and cysteinyl leukotriene-1 receptor blockade as treatment for severe bronchiolitis | |
| UY30935A1 (es) | Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones. | |
| NI200700039A (es) | Derivados de triazolopiridinilsulfanilo como inhibidores de quinasa map p38. | |
| AR030753A1 (es) | Uso de moduladores-proteina de il-8, groalfa, grobeta, grogamma, nap-2, y ena-78, para tratar infecciones viricas | |
| EA200800071A1 (ru) | Производные бензофуранила как ингибиторы 5-нт6-рецептора | |
| EA200400639A1 (ru) | Фармацевтическая комбинация агонистов аденозиновых a-2a и бета-2-адренергических рецепторов | |
| CN106309558A (zh) | 一种鼻腔喷雾剂 | |
| Garg et al. | Tobacco: An invisible and immediate threat for COVID 19 | |
| Rose | Miscellaneous therapy for COVID-19. A systematic review |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |